SCHEMBL12037366

SCHEMBL12037366

CCOC(=O)C1(C(C)=O)C[C@H]1CC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD17B10 Q99714 1/20 0.37
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.33
ATM Q13315 1/20 0.33
F10 P00742 1/20 0.32
ALOX15 P16050 2/20 0.31
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
SOAT1 P35610 1/20 0.31
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31
TUBA3C P0DPH7 1/20 0.31
TUBA1B P68363 1/20 0.31
TUBA4A P68366 1/20 0.31
TUBB4B P68371 1/20 0.31
TUBB3 Q13509 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10953253 1.00 LMNA (0.37) LMNAALDH1A1HSD17B10POLBMAPK1
SCHEMBL15325068 1.00 LMNA (0.37) LMNAALDH1A1HSD17B10POLBMAPK1
SCHEMBL15325943 0.90 ALDH1A1 (0.37) LMNAALDH1A1HSD17B10POLBMAPK1
SCHEMBL11179315 0.90 ALDH1A1 (0.37) LMNAALDH1A1HSD17B10POLBMAPK1
SCHEMBL12037372 0.87 LMNA (0.35) LMNAALDH1A1HSD17B10POLBMAPK1
SCHEMBL7392445 0.85 MAPK1 (0.36) LMNAALDH1A1HSD17B10POLBMAPK1
SCHEMBL7392441 0.85 MAPK1 (0.36) LMNAALDH1A1HSD17B10POLBMAPK1
SCHEMBL15325061 0.85 MAPK1 (0.36) LMNAALDH1A1HSD17B10POLBMAPK1
SCHEMBL7392443 0.85 MAPK1 (0.36) LMNAALDH1A1HSD17B10POLBMAPK1
SCHEMBL15325080 0.84 MAPK1 (0.35) LMNAALDH1A1HSD17B10POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9433621-B2 Substituted pyridine and pyrimidine derivatives and their use in treating viral infections MERCK SHARP & DOHME CORP. (US) 2016-09-06 US disclosed
US-20140242027-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2014-08-28 US disclosed
US-20110318305-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS MERCK SHARP & DOHME LLC 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110318305-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS PNP, XDH, PNPO LMNA 2623/4885ALDH1A1 1973/4885HSD17B10 4033/4885
US-20140242027-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS PNP, XDH, PNPO LMNA 2623/4885ALDH1A1 1973/4885HSD17B10 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.